[미국특허]
Multiple-variable dose regimen for treating TNFα-related disorders
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/395
C07K-016/24
A61K-039/00
출원번호
US-0229722
(2014-03-28)
등록번호
US-8961974
(2015-02-24)
발명자
/ 주소
Hoffman, Rebecca S.
Chartash, Elliot Keith
Taylor, Lori K.
Granneman, George Richard
Yan, Philip
출원인 / 주소
AbbVie Biotechnology Ltd.
대리인 / 주소
Ropes & Gray LLP
인용정보
피인용 횟수 :
4인용 특허 :
32
초록▼
Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase f
Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
대표청구항▼
1. A multiple-variable dose method for treating ulcerative colitis in a subject in need thereof, comprising subcutaneously administering to the subject: a first dose of 160 mg of a recombinant human anti-TNFα antibody administered to the subject within a day; anda second dose of 80 mg of the antibod
1. A multiple-variable dose method for treating ulcerative colitis in a subject in need thereof, comprising subcutaneously administering to the subject: a first dose of 160 mg of a recombinant human anti-TNFα antibody administered to the subject within a day; anda second dose of 80 mg of the antibody administered to the subject within a day, wherein the second dose is administered two weeks following administration of the first dose;wherein the antibody comprises: a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:8; a CDR2 comprising the amino acid sequence of SEQ ID NO:6; and a CDR3 comprising the amino acid sequence of SEQ ID NO:4; anda light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:7; a CDR2 comprising the amino acid sequence of SEQ ID NO:5; and a CDR3 comprising the amino acid sequence of SEQ ID NO:3. 2. The method of claim 1, wherein the heavy chain comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:2, and the light chain comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:1. 3. The method of claim 2, wherein the heavy chain comprises an IgG1 heavy chain constant region and the light chain comprises a kappa light chain constant region. 4. The method of claim 3, wherein the antibody is adalimumab. 5. The method of claim 1, wherein the method further comprises administering to the subject a subsequent subcutaneous injection of 40 mg of the antibody two weeks following administration of the second dose. 6. The method of claim 5, wherein the method further comprises administering to the subject additional subsequent subcutaneous injections of 40 mg of the antibody, wherein the subsequent subcutaneous injections are administered two weeks apart. 7. The method of claim 5, wherein the heavy chain comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:2, and the light chain comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:1. 8. The method of claim 6, wherein the heavy chain comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:2, and the light chain comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:1. 9. The method of claim 7, wherein the heavy chain comprises an IgG1 heavy chain constant region and the light chain comprises a kappa light chain constant region. 10. The method of claim 8, wherein the heavy chain comprises an IgG1 heavy chain constant region and the light chain comprises a kappa light chain constant region. 11. The method of claim 9, wherein the antibody is adalimumab. 12. The method of claim 10, wherein the antibody is adalimumab. 13. The method of claim 1, wherein each subcutaneous injection is administered to the subject using a prefilled syringe. 14. The method of claim 5, wherein each subcutaneous injection is administered to the subject using a prefilled syringe. 15. A multiple-variable dose method for treating ulcerative colitis in a subject in need thereof, comprising subcutaneously administering to the subject: a first dose of 160 mg of a recombinant human anti-TNFα antibody administered as a set of four injections of 40 mg of the antibody administered to the subject within a day; anda second dose of 80 mg of the antibody administered as a set of two injections of 40 mg of the antibody administered to the subject within a day, wherein the second dose is administered two weeks following administration of the first dose;wherein the antibody comprises: a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:8; a CDR2 comprising the amino acid sequence of SEQ ID NO:6; and a CDR3 comprising the amino acid sequence of SEQ ID NO:4; anda light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:7; a CDR2 comprising the amino acid sequence of SEQ ID NO:5; and a CDR3 comprising the amino acid sequence of SEQ ID NO:3. 16. The method of claim 15, wherein the heavy chain comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:2, and the light chain comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:1. 17. The method of claim 16, wherein the heavy chain comprises an IgG1 heavy chain constant region and the light chain comprises a kappa light chain constant region. 18. The method of claim 17, wherein the antibody is adalimumab. 19. The method of claim 15, wherein the method further comprises administering to the subject a subsequent subcutaneous injection of 40 mg of the antibody two weeks following administration of the second dose. 20. The method of claim 19, wherein the method further comprises administering to the subject additional subsequent subcutaneous injections of 40 mg of the antibody, wherein the subsequent subcutaneous injections are administered two weeks apart. 21. The method of claim 19, wherein the heavy chain comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:2, and the light chain comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:1. 22. The method of claim 20, wherein the heavy chain comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:2, and the light chain comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:1. 23. The method of claim 21, wherein the heavy chain comprises an IgG1 heavy chain constant region and the light chain comprises a kappa light chain constant region. 24. The method of claim 22, wherein the heavy chain comprises an IgG1 heavy chain constant region and the light chain comprises a kappa light chain constant region. 25. The method of claim 23, wherein the antibody is adalimumab. 26. The method of claim 24, wherein the antibody is adalimumab. 27. The method of claim 15, wherein each subcutaneous injection is administered to the subject using a prefilled syringe. 28. The method of claim 19, wherein each subcutaneous injection is administered to the subject using a prefilled syringe.
Salfeld,Jochen G.; Allen,Deborah J.; Hoogenboom,Hendricus R. J. M.; Kaymakcalan,Zehra; Labkovsky,Boris; Mankovich,John A.; McGuinness,Brian T.; Roberts,Andrew J.; Sakorafas,Paul; Schoenhaut,David; Va, Human antibodies that bind human TNFα.
Salfeld Jochen G. ; Allen Deborah J.,GBX ; Hoogenboom Hendricus R. J. M. ; Kaymakcalan Zehra ; Labkovsky Boris ; Mankovich John A. ; McGuinness Brian T.,GBX ; Roberts Andrew J.,GBX ; Sakorafas Paul ;, Human antibodies that bind human TNF.alpha..
Salfeld Jochen G. ; Allen Deborah J.,GBX ; Hoogenboom Hendricus R. J. M.,BEX ; Kaymakcalan Zehra ; Labkovsky Boris ; Mankovich John A. ; McGuinness Brian T.,GBX ; Roberts Andrew J.,GBX ; Sakorafas Pa, Human antibodies that bind human TNF.alpha..
Salfeld, Jochen G.; Allen, Deborah J.; Hoogenboom, Hendricus R. J. M.; Kaymakcalan, Zehra; Labkovsky, Boris; Mankovich, John A.; McGuinness, Brian T.; Roberts, Andrew J.; Sakorafas, Paul; Schoenhaut,, Human antibodies that bind human TNFa.
Salfeld, Jochen G.; Allen, Deborah J.; Hoogenboom, Hendricus R. J. M.; Kaymakcalan, Zehra; Labkovsky, Boris; Mankovich, John A.; McGuinness, Brian T.; Roberts, Andrew J.; Sakorafas, Paul; Schoenhaut, David; Vaughan, Tristan J.; White, Michael; Wilton, Alison J., Human antibodies that bind human TNFα.
Salfeld, Jochen G.; Allen, Deborah J.; Hoogenboom, Hendricus R. J. M.; Kaymakcalan, Zehra; Labkovsky, Boris; Mankovich, John A.; McGuinness, Brian T.; Roberts, Andrew J.; Sakorafas, Paul; Schoenhaut, David; Vaughan, Tristan J.; White, Michael; Wilton, Alison J., Human antibodies that bind human TNFα.
Salfeld, Jochen G.; Allen, Deborah J.; Hoogenboom, Hendricus R. J. M.; Kaymakcalan, Zehra; Labkovsky, Boris; Mankovich, John A.; McGuinness, Brian T.; Roberts, Andrew J.; Sakorafas, Paul; Schoenhaut, David; Vaughan, Tristan J.; White, Michael; Wilton, Alison J., Human antibodies that bind human TNFα.
Salfeld, Jochen G.; Mankovich, John A.; Allen, Deborah J.; Hoogenboom, Hendricus R.J.M.; Labkovsky, Boris; McGuinness, Brian T.; Sakorafas, Paul; White, Michael; Wilton, Alison J.; Kaymakcalan, Zehra; Roberts, Andrew J.; Schoenhaut, David; Vaughan, Tristan J., Human antibodies that bind human TNFα and methods of using same.
Maksymowych, Walter P.; Wong, Robert L., Methods and compositions for determining the efficacy of a treatment for ankylosing spondylitis using biomarkers.
Salfeld, Jochen G.; Allen, Deborah J.; Kaymakcalan, Zehra; Labkovsky, Boris; Mankovich, John A.; McGuinness, Brian T.; Roberts, Andrew J.; Sakorafas, Paul; Hoogenboom, Hendricus R. J. M.; Schoenhaut, David; Vaughan, Tristan J.; White, Michael; Wilton, Alison J., Methods for treating rheumatoid arthritis using human antibodies that bind human TNFa.
Salfeld, Jochen G.; Allen, Deborah J.; Kaymakcalan, Zehra; Labkovsky, Boris; Mankovich, John A.; McGuinness, Brian T.; Roberts, Andrew J.; Sakorafas, Paul; Hoogenboom, Hendricus R. J. M.; Schoenhaut, David; Vaughan, Tristan J.; White, Michael; Wilton, Alison J., Methods for treating rheumatoid arthritis using human antibodies that bind human TNFα.
Salfeld, Jochen G.; Allen, Deborah J.; Kaymakcalan, Zehra; Labkovsky, Boris; Mankovich, John A.; McGuinness, Brian T.; Roberts, Andrew J.; Sakorafas, Paul; Hoogenboom, Hendricus R. J. M.; Schoenhaut, David; Vaughan, Tristan J.; White, Michael; Wilton, Alison J., Methods of treating disorders using human antibodies that bind human TNFα.
Stenzel Roswitha,DEX ; Kaul Martin,DEX ; Daum Lothar,DEX ; Kempeni Joachim,DEX ; Raab Christa,DEX ; Schaefer Sibylle,DEX, Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6.
Moodie, Rachel; Hyland, Elizabeth, Methods of treating Crohn's disease or ulcerative colitis using an induction dosing regimen comprising anti-TNF-alpha antibody.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.